0001213900-26-036923
SEC filingPolyPid Ltd. has initiated a rolling New Drug Application submission to the FDA for D-PLEX₁₀₀ to prevent surgical site infections in colorectal surgery patients, with completion expected in the second quarter of 2026.
PolyPid has reached a critical regulatory milestone by initiating the NDA submission process for its lead product candidate D-PLEX₁₀₀, which represents the company's most advanced clinical program. The rolling submission approach under FDA Fast Track designation allows for sequential review of application components, with the clinical section expected in Q2 2026. This submission follows positive Phase 3 SHIELD II trial results showing a statistically significant 60% relative risk reduction in surgical site infections, which provides the clinical foundation for regulatory review. The company's parallel focus on U.S. commercialization partnership negotiations indicates preparation for potential market entry, though actual approval and commercial success remain subject to FDA review and market acceptance. D-PLEX₁₀₀'s Breakthrough Therapy Designation status may facilitate a more efficient review process, potentially accelerating the timeline to potential approval. The company's emphasis on this regulatory milestone reflects its strategic priority to advance D-PLEX₁₀₀ toward commercialization while addressing the significant unmet medical need for surgical site infection prevention.